Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8656 to 8670 of 9079 results

  1. Entinostat for treating hormone receptor-positive breast cancer after hormonal therapy [ID1260]

    Discontinued Reference number: GID-TA10309

    Technology appraisal guidance
    Discontinued

  2. Idebenone for treating Duchenne muscular dystrophy [ID1092]

    Discontinued Reference number: GID-TA10310

    Technology appraisal guidance
    Discontinued

  3. Pembrolizumab for previously treated endometrial cancer [ID1205]

    Discontinued Reference number: GID-TA10243

    Technology appraisal guidance
    Discontinued

  4. Tezacaftor and ivacaftor combination therapy for treating cystic fibrosis with the F508del mutation [ID1303]

    Discontinued Reference number: GID-TA10277

    Technology appraisal guidance
    Discontinued

  5. Pembrolizumab for previously treated metastatic triple negative breast cancer [ID1246]

    Discontinued Reference number: GID-TA10295

    Technology appraisal guidance
    Discontinued

  6. Autologous haematopoietic stem cell transplantation for treating multiple sclerosis [ID1111]

    Discontinued Reference number: GID-TA10306

    Technology appraisal guidance
    Discontinued

  7. Durvalumab with tremelimumab for untreated PD-L1-positive urothelial bladder cancer [ID1335]

    Discontinued Reference number: GID-TA10315

    Technology appraisal guidance
    Discontinued

  8. Durvalumab for untreated metastatic non-small-cell lung cancer with no EGFR- or ALK-positive mutations [ID1331]

    Discontinued Reference number: GID-TA10318

    Technology appraisal guidance
    Discontinued

  9. Vosoritide for treating achondroplasia in people 4 months and over [ID6488]

    In development Reference number: GID-TA11528 Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Netarsudil for treating open angle glaucoma or ocular hypertension [ID1078]

    In development Reference number: GID-TA10431 Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Baricitinib for treating severe or very severe alopecia areata in people 6 to 17 years [ID6541]

    In development Reference number: GID-TA11692 Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Benralizumab for previously treated severe nasal polyps [ID1659]

    Discontinued Reference number: GID-TA10818

    Technology appraisal guidance
    Discontinued

  13. Suspected cancer update

    In development Reference number: GID-QS10176 Expected publication date: TBC

    Quality standard
    In development

  14. Peezy Midstream for urine collection (MT446)

    In development Reference number: GID-HTG10892 Expected publication date: TBC

    HealthTech guidance
    In development

  15. Surgical vessel sealing systems (MT798)

    Discontinued Reference number: GID-HTG10894

    HealthTech guidance
    Discontinued